Skip to Content
Søk Menu

Trastuzumab and HER2 Targeted Cancer Treatment

The success of trastuzumab has inspired the development of several other HER2-targeted drugs and companion diagnostic assays, paving the way for a more objective and effective approach to cancer therapy.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Trastuzumab Deruxtecan Show Maintenance of Overall Health Status and Quality of Life in Patients with HER2 Positive Metastatic Breast Cancers

/ Giuseppe Curigliano
BrystkreftHER2
Arya Mariam Roy

Unraveling the HER2-Low Breast Cancer Puzzle – Treatment Sequencing and Targeted Therapies

/ Arya Mariam Roy
HER2 Play the Video 17:49

HER2-Low Treatment – The Future of this Important Biomarker

/ Paolo Tarantino
BrystkreftHER2Kreft
Paolo Tarantino

Advancements and Emerging Challenges in HER2-Low Treatment

/ Paolo Tarantino
BrystkreftHER2 Play the Video 04:43
Mads Hald Andersen

Insights into Tumor Microenvironment Antigens and Immunomodulation

/ Mads Hald Andersen
AK-behandlingHER2Kreft Play the Video 8:28
Giuseppe Curigliano

DESTINY-Breast03 Study: Trastuzumab Deruxtecan versus Trastuzumab Emtansine

/ Giuseppe Curigliano
HER2 Play the Video 4:44

Pan Tumor Study – Effectively Treatment for HER2-Expressing Cancers Regardless of Tumor Location

/ BestPractice Nordic
ASCO23HER2Kreft
Back to top